Carbon footprint associated with misdiagnosis of asthma in Canada
| A | Prevalence of clinically-diagnosed asthma | 3 800 000 people |
| B | Number of people in ‘A’ who do not have objective evidence of disease | 1 254 000 people |
| C | Number of people in ‘B’ who are using asthma medications | 990 660 people |
| Rescue inhalers | ||
| SABA | ||
| MDI | ||
| D | Number of people in ‘C’ who are using a SABA MDI | 931 220 people |
| E | Carbon footprint associated with SABA MDI use in people in ‘D’ | 12 735 MT CO2e |
| Controller inhalers | ||
| ICS | ||
| MDI | ||
| F | Number of people in ‘C’ who are using an ICS MDI | 76 891 people |
| G | Carbon footprint associated with ICS MDI use in people in ‘F’ | 5 905 MT CO2e |
| ICS/LABA | ||
| MDI | ||
| H | Number of people in ‘C’ who are using an ICS/LABA MDI | 89 118 people |
| I | Carbon footprint associated with ICS/LABA MDI use in people in ‘H’ | 16 866 MT CO2e |
| Total | ||
| J | Carbon footprint of MDIs in misdiagnosed patients | 35 039 MT CO2e |
| K | Carbon footprint of DPIs in misdiagnosed patients – online supplemental appendix A, table S1 | 814 MT CO2e |
| L | Total inhaler carbon footprint due to misdiagnosed patients | 35 852 MT CO2e |
Detailed calculations, supportive information, and additional data on DPIs are presented in online supplemental material 1, appendix A, table S1.
DPI, dry powder inhaler; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; MDI, metred-dose inhaler; MT CO2e, metric tons of CO2 equivalent; SABA, short-acting beta2-agonist.